MOESM3 of A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial

Bradley, Judy; Anand, Rohan; O’Neill, Brenda; Ferguson, Kathryn; Clarke, Mike; Carroll, Mary; Chalmers, James; De Soyza, Anthony; Duckers, Jamie; Hill, Adam; Loebinger, Michael; Copeland, Fiona; Gardner, Evie; Campbell, Christina; Agus, Ashley; McGuire, Alistair; Boyle, Roisin; McKinney, Fionnuala; Dickson, Naomi; McAuley, Danny; Elborn, Stuart

doi:10.6084/m9.figshare.11415381.v1

13063_2019_3766_MOESM3_ESM.docx (40.58 kB)

MOESM3 of A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial

journal contribution

posted on 2019-12-20, 06:29 authored by Judy Bradley, Rohan Anand, Brenda O’Neill, Kathryn Ferguson, Mike Clarke, Mary Carroll, James Chalmers, Anthony De Soyza, Jamie Duckers, Adam Hill, Michael Loebinger, Fiona Copeland, Evie Gardner, Christina Campbell, Ashley Agus, Alistair McGuire, Roisin Boyle, Fionnuala McKinney, Naomi Dickson, Danny McAuley, Stuart Elborn

Additional file 3. Spirometry sub-study.

Funding

National Institute for Health Research

History

Usage metrics

Keywords

Clinical trial protocol Factorial design Bronchiectasis Hypertonic saline Carbocisteine Exacerbation SWAT

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC